Clinical-stage natural psychedelic drug development company Filament Health Corp. FLHLF reported its third quarter financial results and operational highlights for the period ended September 30, 2022.
Numbers show total cash was over $2.6 million (CA$3.5 million), compared to $3.47 million (CA$4.6 million) on the period ended December 31, 2021.
R&D expenses were $133.505 (CA$176,946) and $386.948 (CA$512,854) for the three and the nine months ended September 30, 2022, respectively, as compared to $133.096 (CA$176,403) and $328.104 (CA$434,863) for the same periods ended September 30, 2021.
Net and comprehensive loss was $948.833 (CA$1,257,566) and $3.259.756 (CA$4,320,419) for the three and the nine months ended September 30, 2022, respectively, as compared to $1.251.326 (CA$1,658,484) and $5.193.503 (CA$6,883,371) for the same periods ended September 30, 2021.
CEO Benjamin Lightburn said the period reflected continued progress both internally and externally: “The closure of a $1.8 million (CA$2.5 million) financing provided our drug development platform with significant runway and the issuance of three patents by USPTO and CIPO secured further IP protection.”
Lightburn further stated that the company’s natural psilocybin drug candidate continues to be in high demand from its partner network and was dosed at a large psilocybin clinical trial in which all participants reported positive effects.
Additionally, Filament began the first FDA-approved clinical trial of natural psychedelics together with the University of California San Francisco.
Filament’s CEO concluded: “Looking forward, we are excited by Filament’s growing industry profile as a supplier of pharmaceutical-grade natural psilocybin both for revenue-driving supply partnerships and for research institutions.”
Interestingly, earlier this year the company announced it would participate in the world’s largest medical psilocybin access and data project Project Solace, led by Canadian non-profit Therapsil.
Photo courtesy of PublicDomainPictures, janjf93 on Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!